186 related articles for article (PubMed ID: 33469902)
1. Circulating MicroRNAs and Monocyte-Platelet Aggregate Formation in Acute Coronary Syndrome.
Stojkovic S; Wadowski PP; Haider P; Weikert C; Pultar J; Lee S; Eichelberger B; Hengstenberg C; Wojta J; Panzer S; Demyanets S; Gremmel T
Thromb Haemost; 2021 Jul; 121(7):913-922. PubMed ID: 33469902
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors.
Wadowski PP; Pultar J; Weikert C; Eichelberger B; Lang IM; Koppensteiner R; Panzer S; Gremmel T
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):260-268. PubMed ID: 33107322
[TBL] [Abstract][Full Text] [Related]
4. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y
Panzer B; Wadowski PP; Huber K; Panzer S; Gremmel T
Diabet Med; 2022 Aug; 39(8):e14868. PubMed ID: 35514270
[TBL] [Abstract][Full Text] [Related]
5. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
[No Abstract] [Full Text] [Related]
6. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
7. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
8. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
9. Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Wadowski PP; Kopp CW; Koppensteiner R; Lang IM; Pultar J; Lee S; Weikert C; Panzer S; Gremmel T
Eur J Clin Invest; 2018 Jan; 48(1):. PubMed ID: 29171876
[TBL] [Abstract][Full Text] [Related]
10. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
[TBL] [Abstract][Full Text] [Related]
11. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.
Bonhomme F; Bonvini R; Reny JL; Poncet A; Fontana P
Platelets; 2015; 26(4):324-30. PubMed ID: 25905916
[TBL] [Abstract][Full Text] [Related]
12. Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Lee S; Wadowski PP; Hoberstorfer T; Weikert C; Pultar J; Kopp CW; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2021 Feb; 35(1):51-60. PubMed ID: 32845391
[TBL] [Abstract][Full Text] [Related]
13. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
[TBL] [Abstract][Full Text] [Related]
14. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
[TBL] [Abstract][Full Text] [Related]
15. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Kirkby NS; Leadbeater PD; Chan MV; Nylander S; Mitchell JA; Warner TD
J Thromb Haemost; 2011 Oct; 9(10):2103-5. PubMed ID: 21812912
[No Abstract] [Full Text] [Related]
20. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
